Results 111 to 120 of about 38,544 (277)

Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. [PDF]

, 2011
The relaxed complex scheme, a virtual-screening methodology that accounts for protein receptor flexibility, was used to identify a low-micromolar, non-bisphosphonate inhibitor of farnesyl diphosphate synthase.
Cao, Rong, Durrant, Jacob D, Gorfe, Alemayehu A, Li, Jikun, McCammon, J Andrew, Oldfield, Eric, Sankovsky, Anna, Zhu, Wei   +7 more
core   +2 more sources

Multi‐Targeting Non‐Specific Genome Engineering in Bacteria

Advanced Science, Volume 13, Issue 25, 4 May 2026.
In this study, we provide the first case to use the multi‐targeting integrase (MTI) systems in bacteria and develop a host‐independent generalizable approach, MNGE (Multi‐targeting Non‐specific Genome Engineering), for multi‐copy and random integration of metabolic genes or pathways in both Gram‐positive and Gram‐negative bacteria, which will ...
Runze Sun, Ruixiang You, Yiwen Zhou, Huiyan He, Wenfang Wang, Xudong Qu, Yinhua Lu, Lei Li   +7 more
wiley   +1 more source

Retrotransposon Tto1: functional analysis and engineering for insertional mutagenesis [PDF]

, 2011
Retrotransposons are genomic parasites activated by stress conditions that can be seriously detrimental for their host. In this work I demonstrate that Tto1, a typical plant LTR retrotransposon with insertion preference into genes can be turned into a ...
Tramontano, Andrea, Tramontano, Andrea, Tramontano, Andrea   +2 more
core  

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?

Viruses, 2014
Dolutegravir (DTG) is an HIV integrase inhibitor that was recently approved for therapy by the Food and Drug Administration in the United States. When used as part of first-line therapy, DTG is the only HIV drug that has not selected for resistance ...
Thibault Mesplède, Mark A. Wainberg
doaj   +1 more source

HIV-1 Protease Inhibitors From Marine Brown Alga: A Literature Review [PDF]

, 2017
The human immunodeficiency virus type 1 (HIV-1) causes an infectious disease that if left untreated can progress to acquired immunodeficiency syndrome (AIDS) and be fatal.
Nunez Aguilar, Eric
core   +1 more source

Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection—authors’ response [PDF]

, 2017
Juan Ambrosioni, María Mar Mosquera, José M. Miró   +2 more
openalex   +1 more source

Exploring the impact of Cabotegravir‐Rilpivirine long‐acting on weight gain, body composition and quality of life in adults living with HIV

HIV Medicine, Volume 27, Issue 5, Page 727-739, May 2026.
Abstract Introduction Long‐acting injectable antiretroviral therapy (ART) with Cabotegravir (CAB) and Rilpivirine (RPV) offers an alternative to daily oral regimens, improving adherence and patient satisfaction. However, its impact on body composition and metabolism remains underexplored.
Andrea De Vito, Andrea Marongiu, Antonella Cano, Mariangela Puci, Agnese Colpani, Susanna Maria Nuvoli, Maria Grazia Catte, Giulia Moi, Maria Antonietta Deledda, Sergio Uzzau, Giovanni Sotgiu, Franca Deriu, Angela Spanu, Giordano Madeddu   +13 more
wiley   +1 more source

Gas chromatographic-mass spectrometric (GC-MS) analysis and virtual screening of ripped fruit of Dialium guineense for potential inhibitors of integrase, cycloxygenase-1, and xanthine oxidase [PDF]

, 2022
Patrick Maduabuchi Aja, Peter Chinedu Agu, Boniface Anthony Ale, J.N. Awoke, Hilary Akobi Ogwoni, Muhammad Akram, E. U. Ekpono, I. O. Igwenyi, Patience N. Ogbu, Udu Ama Ibiam, Josiah Esoghene Ifie, Sandra Ifie Etumah, Emmanuel Adegboyega Aboyomi, Daniyal Muhammad, Emmanuel Maduabuchi Ezeh, Onyedika Gabriel Ani   +15 more
openalex   +1 more source

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in people previously treated with darunavir‐based antiretroviral therapy

HIV Medicine, Volume 27, Issue 5, Page 803-808, May 2026.
Abstract Background Darunavir‐based antiretroviral therapy (ART) is commonly used in people with HIV who experience adherence challenges and/or have complex resistance patterns. Changes in ART commissioning have led to an increased use of Bictegravir/Emtricitabine/Tenofovir alafenamide (B/F/TAF) in these populations despite limited real‐world outcome ...
Rhianna Sheridan, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Mark Zuckerman, Sally Hawkins, Kate Childs, Frank A. Post   +6 more
wiley   +1 more source

Pharmacovigilance study of INSTIs associated with weight gain and glucose/lipid metabolism adverse events based on the FDA adverse event reporting system

HIV Medicine, Volume 27, Issue 5, Page 749-760, May 2026.
Abstract Objective Integrase strand transfer inhibitors (INSTIs) are widely used in antiretroviral therapy (ART) for people with HIV due to their efficacy and tolerability. However, concerns about weight gain and metabolic disturbances have emerged.
Leidan Zhang, Ling Chen, Jia Tang, Xiaosheng Liu, Liyuan Zheng, Fada Wang, Xin Huang, Wei Cao, Taisheng Li   +8 more
wiley   +1 more source